Deutsche Bank AG Purchases 50,575 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Deutsche Bank AG boosted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 54.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 142,869 shares of the biotechnology company’s stock after buying an additional 50,575 shares during the period. Deutsche Bank AG owned approximately 0.10% of Aurinia Pharmaceuticals worth $1,283,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $248,000. Union Bancaire Privee UBP SA bought a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $108,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 2,857 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 6,174 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $135,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Greg Keenan sold 12,239 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $97,912.00. Following the transaction, the insider now directly owns 161,789 shares of the company’s stock, valued at approximately $1,294,312. This represents a 7.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Matthew Maxwell Donley sold 65,902 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now owns 739,456 shares in the company, valued at $5,915,648. The trade was a 8.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock worth $2,753,094 in the last ninety days. 4.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Down 2.3%

Shares of Aurinia Pharmaceuticals stock opened at $8.08 on Monday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a twelve month low of $5.11 and a twelve month high of $10.67. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -53.86 and a beta of 1.16. The company’s 50 day moving average is $8.02 and its 200 day moving average is $8.28.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. The firm had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Research analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.